Código QR (código de barras bidimensional)

Favorable response of hepatocellular carcinoma with portal vein tumor thrombosis after radiotherapy combined with atezolizumab plus bevacizumab

Recently, the superiority of atezolizumab plus bevacizumab (AteBeva) over sorafenib was proven in the IMbrave150 trial, and AteBeva became the first-line systemic treatment for untreated, unresectable hepatocellular carcinoma (HCC). While the results are encouraging, more than half of patients with...

תיאור מלא

שמור ב:
Principais autores: Yong Tae Kim, Jina Kim, Jinsil Seong
פורמט: Artigo
שפה:Inglês
יצא לאור: Korean Liver Cancer Association 2023-03-01
סדרה:Journal of Liver Cancer
נושאים:
hepatocellular carcinoma
atezolizumab
bevacizumab
radiotherapy
case reports
גישה מקוונת:http://e-jlc.org/upload/pdf/jlc-2023-02-27.pdf
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים